Johnson & Johnson meets 2 primary endpoints in Phase 3 prostate cancer trial

Johnson & Johnson said its Phase 3 prostate cancer study met both co-primary endpoints, clearing a path toward regulatory submission for what could become a multibillion-dollar oncology franchise.

"These results represent a significant milestone for patients with prostate cancer," a company spokesperson said, confirming the topline readout.

The trial evaluated an investigational treatment for patients with a form of advanced prostate cancer. J&J did not disclose the specific drug name, efficacy data, or safety profile, saying full results would be presented at an upcoming medical meeting. The company also did not disclose the size of the patient population or the specific co-primary endpoints achieved.

Prostate cancer is the second most common cancer in men globally, with about 1.5 million new cases diagnosed each year. The successful readout strengthens J&J's oncology pipeline, which already includes approved therapies for prostate and other solid tumors. The company faces competition from Pfizer's recently reported TALAPRO-3 study, which showed a 52% reduction in the risk of radiographic progression or death in a similar patient population.

The positive data de-risks the drug's path to regulatory filing. J&J is expected to submit the results to the US Food and Drug Administration and other global health authorities in the coming months. Analysts will watch for the full data disclosure to assess the drug's differentiation versus existing therapies, including Pfizer's talazoparib (Talzenna) combination and Astellas' enzalutamide (Xtandi). J&J shares may see upside as the market prices in a potential new revenue stream in the $10 billion-plus prostate cancer treatment market.

This article is for informational purposes only and does not constitute investment advice.